Business Strategy

Our strategy is to develop key transrenal DNA and RNA tests initially for particular infectious diseases and for early tumor detection and therapeutic monitoring. These efforts are to be soon followed by development of diagnostics for the areas of oncology, transplantation monitoring and prenatal genetic testing.

We believe that these goals can be reached in partnership with other companies who have the capability of bringing our technology forward in the form of diagnostic products to a global market. This is heralded by early introduction of products for research in order to inform and enable development of a broad range of potentially important commercial applications.

Furthermore, Xenomics believes that its strong intellectual property base can provide access to markets for other companies who otherwise would be limited to costly invasive testing such as tests performed on blood, sputum, tissue and other types of specimens.

The Market Opportunity
Tr-DNA technology has the opportunity to foster fundamental improvements in safety, accuracy and functionality of diagnostic testing, currently a $1.5 billion segment of the healthcare industry. Further, it has the ability to create new markets, such as monitoring the effectiveness of cancer therapies or the health of transplanted organs, non-invasive prenatal genetic testing, detection of pathogens resident in inaccessible tissues, et cetera.

Xenomics intends to develop this platform technology into a pipeline of potentially groundbreaking commercial medical testing products for the detection and/or monitoring of diverse diseases and health conditions, including prenatal conditions, cervical cancer, tuberculosis, HIV/AIDS, and numerous other applications.

Immediate Product Development Focus
By the beginning of 2009, Xenomics expects to enter the world market with a urine-based HPV assay and a Gender Determination assay.

Xenomics´ immediate product focus is in the areas of human papillomavirus (HPV) for FDA approval, tuberculosis, and oncology. Xenomics is also developing a microRNA isolation kit from urine and several disease- and organ-specific microRNA detection kits.